西亚试剂：The E3 ligase Cbl-b and TAM receptors regulate cancer me-ta

发布时间：2025-08-06

Magdalena Paolino, Axel Choidas, Stephanie Wallner, Blanka Pranjic, Iris Uribesalgo,Stefanie Loeser, Amanda M. Jamieson, Wallace Y. Langdon, Fumiyo Ikeda, Juan Pablo Fededa, Shane J. Cronin, Roberto Nitsch, Carsten Schultz-Fademrecht, Jan Eickhoff,Sascha Menninger, Anke Unger, Robert Torka, Thomas Gruber, Reinhard Hinterleitner,Gottfried Baier, Dominik Wolf, Axel Ullrich, Bert M. Klebl & Josef M. Penninger

 

Tumour me-tastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies. Here we show that genetic deletion of the E3 ubiquitin ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 ligase activity licenses natural killer (NK) cells to spontaneously reject me-tastatic tumours. The TAM tyrosine kinase receptors Tyro3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-me-tastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary cancer and melanoma me-tastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-me-tastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in cancer biology. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a ‘pill’ that awakens the innate immune system to kill cancer me-tastases.

以上资料由西亚试剂：http://www.xiyashiji.com/ 提供

上一篇：探索天然蘑菇化合物治疗精神疾病的潜力
下一篇：内蒙古确诊两名肺鼠疫患者